您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Butyrolactone 3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Butyrolactone 3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Butyrolactone 3图片
CAS NO:778649-18-6
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt184.2
Cas No.778649-18-6
FormulaC9H12O4
Solubility≤14mg/ml in ethanol;14mg/ml in DMSO;13mg/ml in dimethyl formamide
Chemical Namerel-tetrahydro-4-methylene-5-oxo-2R-propyl-3S-furancarboxylic acid
Canonical SMILESO=C1C([C@@H](C(O)=O)[C@H](CCC)O1)=C
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 100 μM

Butyrolactone 3 is a histone acetyltransferase Gcn5 inhibitor.

The human histone acetyltransferase Gcn5 is identified as a prominent member of the GNAT family with high preference for histone H3 as a substrate.

In vitro: The analogs of butyrolactone 3 only showed a weak inhibition of CBP, while butyrolactone 3 led to an inhibition of Gcn5. It was important to see that in the presence of acetyl-CoA the Kd value for binding of histone H3 to Gcn5 or PCAF was around 100 mM. Moreover, the affinity of butyrolactone 3 to the Gcn5 enzyme was found to be comparable to that of the natural substrate H3 and could provide an good starting point for the study of SAR. In addition, a nonirreversible inhibition of Gcn5 could be determine, and thus a Michael addition of nucleophilic groups of the enzymeBs active side was unlikely. Therefore, the derivatization of gbutyrolactone 3 at position 2 might be a promising starting point for future SAR studies [1].

In vivo: So far, there is no animal in vivo data reported.

Clinical trial: Up to now, Butyrolactone 3 is still in the preclinical development stage.

Reference:
1.  M. Biel, A. Kretsovali, E. Karatzali, et al. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angewandte Chemie International Edition 43, 3974-3976 (2004).